<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Kidney transplantation in adults: Posttransplant erythrocytosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Kidney transplantation in adults: Posttransplant erythrocytosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Kidney transplantation in adults: Posttransplant erythrocytosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Demetrios V Vlahakos, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sami Alasfar, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Vella, MD, FACP, FRCP, FASN, FAST
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Posttransplant erythrocytosis (PTE) occurs in 8 to 15 percent of kidney transplant recipients and usually affects patients with well-preserved graft function [
         <a href="#rid1">
          1-4
         </a>
         ]. The pathogenesis, clinical features, diagnosis, and treatment of this disorder are reviewed here. An overview of the general approach to the patient with polycythemia is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Posttransplant erythrocytosis (PTE) is defined as persistently elevated hemoglobin and hematocrit levels that occur following kidney transplantation and persist for more than six months in the absence of thrombocytosis, leukocytosis, or another potential cause of erythrocytosis [
         <a href="#rid1">
          1-5
         </a>
         ]. Although the terms erythrocytosis and polycythemia are often used interchangeably, erythrocytosis is used to describe the condition of increased red blood cell mass in transplant patients.
        </p>
        <p>
         The threshold used to define PTE is variable. Some studies have used cutoff values of hematocrit (50 to 54 percentage points) or hemoglobin (16.5 to 18 g/dL), whereas others have used a cutoff value of actual red cell mass. Some studies have used the same threshold to define PTE in both males and females, while others have used separate sex-based cutoffs [
         <a href="#rid1">
          1-4,6-12
         </a>
         ]. Most clinicians use a hematocrit threshold of 51 percent (corresponding to a hemoglobin concentration of approximately 17 g/dL) for both males and females [
         <a href="#rid2">
          2,6,13-20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia", section on 'Causes of absolute polycythemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3879340091">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTE occurs in 8 to 15 percent of kidney transplant recipients; a few studies have reported incidences as high as 22 percent [
         <a href="#rid1">
          1-5,7
         </a>
         ]. The disparity in reported prevalence is due in part to the variably defined hematocrit thresholds used and the inclusion of transitory erythrocytosis (ie, persisting for less than six months) [
         <a href="#rid2">
          2
         </a>
         ]. Differences in immunosuppressive regimens may also contribute to disparities between centers in the reported prevalence of PTE since individual agents have variable effects on hemoglobin.
        </p>
        <p>
         The incidence of PTE appears to be decreasing. Erythrocytosis defined as hemoglobin &gt;17 g/dL was reported in 19 percent of those transplanted between 1993 and 1996 but only 8 percent of those transplanted between 1997 and 2005 and 7 percent of those transplanted between 2010 and 2013 [
         <a href="#rid4">
          4,21
         </a>
         ]. The more widespread use of angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         in the more recently transplanted cohort are likely responsible for this trend. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H719588705">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential risk factors associated with posttransplant erythrocytosis (PTE) include male sex, younger age, a rejection-free course, preserved glomerular filtration rate (GFR), hypertension, diuretic use, use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and longer duration of dialysis [
         <a href="#rid2">
          2,5,6,9,10,22,23
         </a>
         ]. Smoking history and diabetes have been shown to increase the risk of PTE in some [
         <a href="#rid6">
          6,9
         </a>
         ], but not all, studies [
         <a href="#rid4">
          4,5,11
         </a>
         ]. Almost all cases of PTE develop in transplant recipients who have retained native kidneys [
         <a href="#rid5">
          5,24-27
         </a>
         ]. PTE seems to be less likely if the donor suffered from diabetes, hypertension, or cerebrovascular events [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Some patients appear to be particularly susceptible to PTE, suggesting that patient-specific factors play a role. As an example, in one report of a patient who underwent two transplants, PTE occurred after both surgeries, despite the presence of severe anemia in the intervening 12 months between transplantation of the first and second graft [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         The original cause of end-stage kidney disease (ESKD) also affects the risk of PTE. Patients with polycystic kidney disease (PKD) and glomerulonephritis were more likely to develop PTE in some studies [
         <a href="#rid11">
          11
         </a>
         ]. Renal artery stenosis of the native or transplanted kidney was suggested as a risk factor for PTE in early case reports, but this has not been confirmed in subsequent studies [
         <a href="#rid2">
          2,6,28,29
         </a>
         ].
        </p>
        <p>
         PTE may be more common among recipients of simultaneous pancreas-kidney transplantation. This was suggested by a retrospective analysis of 94 simultaneous pancreas and kidney transplant recipients, 174 living-, related-donor recipients, and 53 type 1 diabetic kidney transplant recipients [
         <a href="#rid30">
          30
         </a>
         ]. Patients who received a simultaneous pancreas-kidney transplant had a higher incidence of PTE, compared with living, related kidney transplant recipients (16 versus 3 percent, respectively). There were no instances of PTE among the 53 diabetic kidney transplant recipients. (See
         <a class="medical medical_review" href="/z/d/html/7313.html" rel="external">
          "Pancreas-kidney transplantation in diabetes mellitus: Benefits and complications", section on 'Posttransplant erythrocytosis (PTE)'
         </a>
         .)
        </p>
        <p>
         Risk factors for nontransplant-associated erythrocytosis, such as renal cell cancer, breast cancer, hepatocellular carcinoma, chronic obstructive pulmonary disease (COPD), cerebellar hemangiomas, uterine myomata, and pheochromocytoma, are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia", section on 'Causes of absolute polycythemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of posttransplant erythrocytosis (PTE) is multifactorial and not well understood.
        </p>
        <p>
         A number of hormonal systems and growth factors have been implicated in the pathogenesis of PTE, as discussed below.
        </p>
        <p class="headingAnchor" id="H2873640898">
         <span class="h2">
          Increased erythropoietin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased erythropoietin has been shown in many [
         <a href="#rid24">
          24,31,32
         </a>
         ], though not all [
         <a href="#rid1">
          1,13,32,33
         </a>
         ], studies. As an example, in one study, serum erythropoietin concentrations were elevated in six of seven patients with PTE [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Even among PTE patients with serum erythropoietin concentrations within normal range, the concentration may be inappropriately elevated for a given hemoglobin. In one study, the mean observed/expected serum erythropoietin ratio was elevated among 13 PTE patients compared with that of 42 kidney transplant recipients without erythrocytosis (8.6 versus 0.3, respectively) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         The demonstration of increased, or even normal, erythropoietin levels suggests that PTE may be a form of "tertiary hypererythropoietinemia," in which mechanisms that suppress erythropoietin synthesis or secretion and are normally provoked by a normal or elevated hematocrit do not function adequately [
         <a href="#rid2">
          2,24
         </a>
         ].
        </p>
        <p>
         The source of excess erythropoietin appears to be the native kidney [
         <a href="#rid24">
          24,31
         </a>
         ]. This was suggested by one detailed study of three patients that demonstrated higher blood erythropoietin titers obtained by selective catheterization from the renal veins of native kidneys versus transplanted kidneys (41 versus 13 mU/mL, respectively). In one patient, erythropoietin titers and hematocrit were decreased within two weeks of bilateral native nephrectomy.
        </p>
        <p>
         With the exception of phlebotomy, therapies that correct PTE are generally accompanied by a reduction in erythropoietin levels and/or normalization of the erythropoietin versus hematocrit relationship. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H223341273">
         <span class="h2">
          Other hematopoietic growth factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other hematopoietic factors, including insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding proteins, the serum-soluble stem cell factor (sSCF), and immunoglobulin A1 (IgA1), may either enhance the sensitivity to erythropoietin or directly promote erythropoiesis in patients with PTE [
         <a href="#rid1">
          1,34-36
         </a>
         ]. In one study, cultured erythroid progenitors from patients with PTE were shown to have increased sensitivity to erythropoietin in vitro compared with erythroid progenitors from transplant recipients with normal hematocrits [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Increased concentrations of plasma IGF-1 and/or its major binding proteins have been demonstrated in patients with PTE compared with transplant recipients with normal hematocrits [
         <a href="#rid33">
          33
         </a>
         ]. The mechanisms underlying increased IGF-1 concentrations are not entirely clear. In vitro studies have shown an interaction between IGF-1 and angiotensin II at several levels, and clinical observations suggest that angiotenin-converting enzyme (ACE) inhibitors decrease circulating IGF-1 levels in patients with hypertension [
         <a href="#rid38">
          38
         </a>
         ]. In one series of 40 PTE patients, for example, treatment with an ACE inhibitor reduced concentrations of both erythropoietin and IGF-1 from 15.4±6.2 to 11.2±6.8 mU/mL and from 364±99 to 280±129 ng/mL, respectively [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Activation of renin-angiotensin system'
         </a>
         below.)
        </p>
        <p>
         sSCF, which stimulates the growth of erythroid progenitor cells [
         <a href="#rid36">
          36
         </a>
         ], has been shown to correlate with both hematocrit values and with the observed/expected erythropoietin values in PTE patients, suggesting a possible role in pathogenesis [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         A number of observations have indicated that IgA1, which has been implicated in the pathogenesis of IgA nephropathy (IgAN), can also regulate erythropoiesis. First, in large cohorts of patients with chronic kidney disease, IgAN has been associated with erythrocytosis in 3.5 percent of patients [
         <a href="#rid39">
          39
         </a>
         ]. Secondly, after kidney transplantation, anemia recovery is faster in patients with IgAN. Thirdly, IgA1 from patients with IgAN and erythrocytosis increases the sensitivity of erythroid progenitors to erythropoietin. And finally, elevated hematocrit values were observed in A1 knock-in mice compared with wild-type counterparts.
        </p>
        <p class="headingAnchor" id="H3784133997">
         <span class="h2">
          Activation of renin-angiotensin system
         </span>
         <span class="headingEndMark">
          —
         </span>
         Activation of the renin-angiotensin system (RAS) and especially angiotensin II, its active octapeptide, may contribute to PTE by acting as a direct growth factor on erythroid progenitors and stimulating erythropoietin secretion [
         <a href="#rid40">
          40-42
         </a>
         ]. In this regard, activation of the angiotensin II receptor in PTE patients may enhance erythropoietin production in the graft or the native kidneys and directly activate red cell precursors in the bone marrow [
         <a href="#rid14">
          14,41,43-49
         </a>
         ]. In addition, angiotensin II may induce hypoxia-inducible factor, a transcription factor that promotes the production of erythropoietin, and augment iron metabolism through alterations of iron transporters [
         <a href="#rid50">
          50-52
         </a>
         ]. However, in a study with 331 consecutive transplant recipients, there was no association of polymorphic variants of the ACE, angiotensinogen, and angiotensin II receptor type 1 genes with PTE [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Nevertheless, experimental observations in genetically manipulated animals suggest an interrelationship between RAS activation and augmented erythropoiesis. In mice that carry both the human renin and angiotensinogen genes, development of hypertension is accompanied by higher hematocrit values, increased serum erythropoietin levels, and enhanced expression of erythropoietin messenger RNA. Both blood pressure and hematocrit remain normal when the two transgenes are introduced into the angiotensin II receptor null background, an observation that highlights the pivotal role of this receptor in both mediating sustained hypertension and regulating erythropoiesis. By contrast, in angiotensinogen, ACE, and angiotensin II receptor knock-out animals, lowering of blood pressure is coupled with decreased hematocrit values. In angiotensinogen and renin knock-out animals, anemia is rescued by angiotensin II infusion, an effect that is completely blocked by simultaneous administration of angiotensin II receptor blockers [
         <a href="#rid46">
          46,54
         </a>
         ].
        </p>
        <p>
         Similarly, clinical data indirectly support the role of the RAS system in erythropoiesis. As an example, erythrocytosis has been reported in patients with renin-secreting juxtaglomerular cell tumors and in patients with Bartter syndrome, a condition characterized by hyperreninemia [
         <a href="#rid55">
          55,56
         </a>
         ]. RAS inactivation by ACE inhibitors and angiotensin receptor blockers (ARBs) reduces erythropoiesis but rarely causes clinically significant anemia in the vast majority of otherwise uncomplicated patients [
         <a href="#rid40">
          40,57-66
         </a>
         ]. However, a significant hematocrit-lowering effect and/or anemia due to administration of ACE inhibitors or ARBs has been reported in various forms of secondary polycythemias, including high altitude polycythemia and hypoxia-associated polycythemia in patients with chronic obstructive pulmonary disease, and when the bone marrow requires all available stimuli to augment erythropoiesis, such as in patients with kidney function impairment, heart failure, or an immunosuppressed state. By contrast, increased hematocrit values and decreased need for exogenous erythropoietin administration have been reported after discontinuation of RAS inhibitors in patients with lower-risk myelodysplastic syndromes [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         The mechanisms by which ACE inhibitors and ARBs inhibit erythropoiesis are incompletely defined, and some effects may not be common to both classes of drugs. As an example, ACE inhibitors, but not ARBs, cause an increase in the protein Ac-SDKP (goralatide) [
         <a href="#rid44">
          44-46,68
         </a>
         ]. Goralatide inhibits multipotent hematopoietic stem cell entry into S phase and is usually metabolized by ACE, thereby diminishing erythropoiesis. However, this mechanism does not explain the effectiveness of ARBs in correcting PTE, suggesting that other mechanisms are also operative.
        </p>
        <p>
         Some studies have shown that, among PTE patients with normal or high erythropoietin concentrations, the ACE inhibitor-induced reduction in hematocrit is associated with a fall in plasma erythropoietin concentrations, suggesting an erythropoietin-dependent mechanism [
         <a href="#rid13">
          13,69
         </a>
         ]. However, ACE inhibitors are also effective among patients whose erythropoietin concentrations are initially suppressed or do not fall significantly after therapy is begun, suggesting that these agents may also act via an erythropoietin-independent mechanism [
         <a href="#rid1">
          1,13,70
         </a>
         ]. Also compatible with an erythropoietin-independent mechanism is the observation that withdrawal of the ACE inhibitor in patients with PTE results in a gradual rise in hematocrit without a concurrent elevation in erythropoietin levels [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         In patients with diabetes, who frequently have increased glucose reabsorption by sodium-glucose cotransporters (SGLTs), the high glucose environment in the renal tubulointerstitium may damage renal erythropoietin-producing cells and cause decreased erythropoietin secretion [
         <a href="#rid71">
          71
         </a>
         ]. Inappropriately low erythropoietin levels for the degree of anemia have been reported in patients with diabetes mellitus [
         <a href="#rid72">
          72
         </a>
         ], and anemia develops earlier and is more severe in patients with diabetes and kidney disease than in their counterparts with nondiabetic kidney disease [
         <a href="#rid73">
          73
         </a>
         ]. Correction of diabetes in simultaneous kidney-pancreas recipients is associated with higher prevalence of PTE than in same-donor single kidney recipients (38.5 versus 7.7 percent) [
         <a href="#rid74">
          74
         </a>
         ]. Similarly, SGLT2 inhibitors, which block glucose reabsorption, may attenuate glucotoxicity and allow erythropoietin-producing cells to resume their function. Erythropoietin levels increase within weeks after treatment with an SGLT2 inhibitor, followed by increased reticulocyte count and hematocrit values that peak after two to three months [
         <a href="#rid75">
          75
         </a>
         ]. Thus, wider adoption of SGLT2 inhibitors in the treatment of kidney transplant recipients with high-normal hematocrit values may increase the incidence of PTE [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2662106967">
         <span class="h2">
          Endogenous androgens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endogenous androgens may play a role in the development of PTE. Male sex is one of the most important risk factors for the development of PTE [
         <a href="#rid2">
          2
         </a>
         ]. Androgens directly stimulate erythroid progenitors [
         <a href="#rid76">
          76
         </a>
         ] and indirectly promote erythropoiesis by stimulating either endogenous erythropoietin [
         <a href="#rid77">
          77
         </a>
         ] or the RAS [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         One study sought to determine whether angiogenic factors contribute to PTE [
         <a href="#rid79">
          79
         </a>
         ]. Serum vascular endothelial growth factor (VEGF) levels were measured in 13 patients with PTE, 75 untreated erythrocytosis nontransplant patients, and 21 healthy controls. The results indicated that VEGF was overproduced in advanced and untreated polycythemia vera (PV) patients and to a lesser degree in idiopathic erythrocytosis, but there was no evidence of increased VEGF in PTE and in secondary erythrocytosis. The absence of angiogenesis in PTE and its presence in PV demonstrates that the pathogenesis of these two entities is different. This might explain the relatively benign course of PTE.
        </p>
        <p class="headingAnchor" id="H719588281">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Posttransplant erythrocytosis (PTE) usually occurs 8 to 24 months after transplantation [
         <a href="#rid5">
          5
         </a>
         ], with hemoglobin/hematocrit levels increasing gradually over a period of months. There is no correlation between hemoglobin/hematocrit concentration and symptoms, and routine monitoring of the complete blood count is required to detect PTE.
        </p>
        <p>
         Patients with PTE may experience symptoms such as malaise, headache, plethora, lethargy, and dizziness, though robust studies assessing the prevalence of these symptoms in the modern era of immunosuppression are lacking. Historically, thromboembolic complications (deep vein thrombosis, pulmonary embolus, thrombophlebitis, or stroke) were relatively common in untreated patients with PTE (18 percent in one study [
         <a href="#rid6">
          6
         </a>
         ]); however, subsequent studies of patients undergoing treatment with ACE inhibitors or ARBs for PTE have shown very low rates of thrombosis [
         <a href="#rid80">
          80,81
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4534.html" rel="external">
          "Polycythemia vera and secondary polycythemia: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         Platelet and leukocyte counts are normal, and arterial blood gases are normal in patients with PTE [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Without treatment, PTE spontaneously remits in approximately one-fourth of patients within two years and in approximately two-thirds of patients within five years from its onset [
         <a href="#rid21">
          21
         </a>
         ]. However, in some cases, PTE may persist for several years and eventually remit in the setting of deteriorating allograft function due to chronic rejection [
         <a href="#rid7">
          7,30
         </a>
         ]. A retrospective single-center analysis of 4317 kidney transplants found that with appropriate management, there was no significant association between PTE and patient mortality, graft survival, or vascular thromboembolism [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of posttransplant erythrocytosis (PTE) is made by the demonstration of a hemoglobin &gt;17 g/dL and/or hematocrit &gt;51 percent that persists for over six months after transplantation and by the exclusion of common causes of nontransplant-associated erythrocytosis, including malignancies and, in selected patients, chronic obstructive pulmonary disease (COPD) or obstructive sleep apnea (OSA). (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia", section on 'Initial evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2097284428">
         <span class="h2">
          Confirmation of persistent erythrocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of PTE should be suspected in any kidney transplant recipient who is found to have a hemoglobin &gt;17 g/dL and/or hematocrit &gt;51 percent for more than two to three months. An elevated hemoglobin/hematocrit level lasting more than six months confirms the presence of persistent erythrocytosis.
        </p>
        <p>
         All patients with an elevated hemoglobin/hematocrit level should be evaluated for the possibility of hemoconcentration (ie, an elevation of hemoglobin/hematocrit due to a decrease in plasma volume without an increase of the red blood cell mass) as a potential cause of the abnormal elevation. In general, extracellular volume contraction leading to hemoconcentration is an acute event and is not likely to result in a sustained elevation in hemoglobin/hematocrit levels for prolonged periods of time.
        </p>
        <p class="headingAnchor" id="H2670505887">
         <span class="h2">
          Exclusion of nontransplant causes of erythrocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney transplant recipients who are found to have persistent erythrocytosis (see
         <a class="local">
          'Confirmation of persistent erythrocytosis'
         </a>
         above) should undergo a diagnostic evaluation to exclude nontransplant causes of erythrocytosis. In general, the diagnostic evaluation of PTE is different from that of erythrocytosis in a patient who has not received a transplant, since transplant patients receive a thorough evaluation prior to surgery, during which a baseline hemoglobin is established and longstanding pulmonary disease and congenital disorders are excluded. The evaluation focuses on acquired disorders that may contribute to erythrocytosis and for which the transplant population is at higher risk, including malignancies such as renal cell carcinoma and breast cancer:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We obtain an ultrasound with Doppler waveform analysis of renal arteries of the native and transplanted kidney to exclude renal artery stenosis. If this study is suspicious for renovascular hypertension, further evaluation is performed. (See
         <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">
          "Hypertension after kidney transplantation", section on 'Evaluation for transplant renal artery stenosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform a kidney ultrasound to exclude an underlying renal carcinoma. This is typically performed at the same time as the ultrasound evaluation for renal artery stenosis. If the ultrasound is suspicious for malignancy, further evaluation is performed. (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In females, we obtain a mammogram if one has not been obtained within one year to exclude breast cancer. (See
         <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">
          "Screening for breast cancer: Strategies and recommendations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with a history of hepatitis B or C virus infection who are at increased risk for hepatocellular carcinoma, we obtain a liver ultrasound and serum alfa fetoprotein (AFP) concentration to screen for hepatocellular carcinoma. (See
         <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">
          "Epidemiology and risk factors for hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with a smoking history exceeding 20 years or a clinical history of COPD, a chest radiograph, pulmonary function tests, and arterial blood gases may be obtained as hypoxemia and COPD are common causes of nontransplant-associated erythrocytosis. However, as noted above, these tests have generally been performed prior to transplantation, and the utility of repeating this evaluation is not clear, since transplantation-associated erythrocytosis usually occurs within a few months following transplantation. (See
         <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">
          "Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Diagnostic Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with signs and symptoms suggestive of OSA (eg, daytime sleepiness; snoring, gasping, or choking during sleep), we obtain diagnostic testing for OSA. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         We do not perform imaging studies to rule out other uncommon causes of erythrocytosis such as hemangioblastomas, pheochromocytoma, or uterine myomata unless there is an additional indication besides the presence of erythrocytosis.
        </p>
        <p>
         We do not measure erythropoietin concentrations as part of the diagnostic evaluation of PTE. In contrast with the general population with erythrocytosis, the measurement of erythropoietin concentrations is not helpful among transplant recipients, since high and low concentrations have been demonstrated among PTE patients.
        </p>
        <p>
         Measurement of renin-angiotensin system (RAS) activity, goralatide, or insulin-like growth factor-1 (IGF-1) concentrations are also not helpful in making the diagnosis or direct treatment and are not performed among transplant recipients.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2266878278">
         <span class="h2">
          Overview of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all kidney transplant recipients who have posttransplant erythrocytosis (PTE), we suggest treatment to lower the hemoglobin concentration. The primary goals of treatment are to control symptoms and reduce the risk of thromboembolic events (see
         <a class="local">
          'Clinical presentation'
         </a>
         above). Although there are no studies that have shown that reducing hemoglobin levels in patients with PTE is associated with an improvement in symptoms or reduction in thrombosis risk, extensive data in patients with polycythemia vera (a chronic myeloproliferative disorder associated with an elevated red blood cell mass) support this approach. (See
         <a class="medical medical_review" href="/z/d/html/4534.html" rel="external">
          "Polycythemia vera and secondary polycythemia: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         The optimal hemoglobin among patients with PTE is not known. We generally target a hemoglobin level &lt;17 g/dL (hematocrit &lt;51 percent) in both males and females. Our overall approach to therapy, which is largely consistent with the guidelines of the British Society of Haematology [
         <a href="#rid83">
          83
         </a>
         ], is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In all patients with PTE and a hemoglobin &gt;17 g/dL, we suggest either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) as initial treatment. (See
         <a class="local">
          'ACE inhibitors or ARBs in all patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with PTE who have a contraindication to receiving an ACE inhibitor or ARB (eg, due to intolerance or known allergy) or in whom an ACE inhibitor or ARB is ineffective at reducing the hemoglobin concentration, we suggest therapeutic phlebotomy. (See
         <a class="local">
          'Phlebotomy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         We do not routinely use
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         or an antiproliferative agent (eg,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ) as initial therapy in patients with PTE. However, these agents can be considered for patients who do not respond to ACE inhibitors or ARBs or who have a contraindication to their use and who do not wish to undergo repeated phlebotomy. (See
         <a class="local">
          'Less frequently used therapies'
         </a>
         below.)
        </p>
        <p>
         There are no data evaluating the use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         in patients with PTE. However, in transplant recipients with PTE who have risk factors for coronary heart disease, we administer aspirin for primary prevention of cardiovascular events. (See
         <a class="medical medical_review" href="/z/d/html/7314.html" rel="external">
          "Risk factors for cardiovascular disease in the kidney transplant recipient"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">
          "Aspirin in the primary prevention of cardiovascular disease and cancer"
         </a>
         .)
        </p>
        <p>
         We continue therapy for PTE indefinitely since relapse of erythrocytosis is common if treatment is discontinued and because the majority of kidney transplant recipients are hypertensive and would benefit from treatment with an ACE inhibitor or ARB. In addition, ACE inhibitors and ARBs may slow the rate of progressive kidney dysfunction [
         <a href="#rid2">
          2,25,84
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
         Patients with PTE who develop an acute thromboembolic event should be managed similarly to patients with polycythemia vera or other forms of secondary erythrocytosis who have thromboembolic complications. (See
         <a class="local">
          'Patients with a thromboembolic event'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4025483106">
         <span class="h2">
          ACE inhibitors or ARBs in all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients with PTE and a hemoglobin level &gt;17 g/dL, our preferred initial treatment is an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). These agents are effective in the majority of patients, are reasonably safe, and, among many patients, provide a necessary antihypertensive effect.
        </p>
        <p>
         If the patient has a contraindication to receiving an ACE inhibitor or ARB (eg, due to intolerance or known allergy), we treat with therapeutic phlebotomy (see
         <a class="local">
          'Phlebotomy'
         </a>
         below). Some patients may not wish to undergo repeated phlebotomy; in such patients,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         or an antiproliferative agent
         <strong>
         </strong>
         may be an effective alternative therapy. (See
         <a class="local">
          'Less frequently used therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2774188845">
         <span class="h3">
          Dosing of ACE inhibitors/ARBs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice between an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) is dependent upon patient and clinician preference; although limited data suggest that ACE inhibitors may be somewhat more effective in lowering the hemoglobin, they are more likely than ARBs to produce side effects. (See
         <a class="local">
          'Evidence for ACE inhibitors/ARBs'
         </a>
         below.)
        </p>
        <p>
         We initiate therapy with an ARB, such as
         <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">
          losartan
         </a>
         at 50 mg/day. If the hemoglobin level does not decrease to &lt;17 g/dL within four weeks or if blood pressure remains elevated, the dose may be increased to 100 mg/day. If an adequate lowering of the hemoglobin is not seen after an additional four weeks, we replace losartan with
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         , administered at 10 to 40 mg daily, or an equivalent dose of another ACE inhibitor.
        </p>
        <p>
         If the ACE inhibitor or ARB is effective at reducing the hemoglobin concentration, we continue the ACE inhibitor or ARB indefinitely, given that relapse is common when treatment is discontinued. Patients are subsequently monitored with a complete blood count monthly to every three months per routine monitoring for kidney transplant recipients. (See
         <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">
          "Overview of care of the adult kidney transplant recipient", section on 'Routine follow-up and laboratory monitoring'
         </a>
         .)
        </p>
        <p>
         In our experience, approximately 5 to 10 percent of patients will not respond to an ACE inhibitor or ARB; such patients are generally unresponsive to all other ACE inhibitors and ARBs. We do
         <strong>
          not
         </strong>
         use combination therapy with both an ACE inhibitor and an ARB in these patients. If an ARB or ACE inhibitor is ineffective at reducing the hemoglobin concentration at the maximum tolerated dose, we treat the patient with serial phlebotomy. In such patients, we typically continue the ARB or ACE inhibitor, particularly if hypertension is also present. If the patient does not wish to undergo repeated phlebotomy,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         or an antiproliferative agent may be an effective alternative therapy. (See
         <a class="local">
          'Phlebotomy'
         </a>
         below and
         <a class="local">
          'Less frequently used therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2247136289">
         <span class="h3">
          Evidence for ACE inhibitors/ARBs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) [
         <a href="#rid1">
          1,2,13,15,25,69,70,84-88
         </a>
         ] have been used to correct PTE. A 2007 systematic review of eight randomized trials including 231 transplant recipients showed that treatment with either an ACE inhibitor or ARB significantly lowered the hematocrit compared with control patients [
         <a href="#rid89">
          89
         </a>
         ]. Although this systematic review did not specifically include patients with PTE, in trials with at least 12 months of follow-up, the hematocrit was on average 3.5 percent lower (1.2 g/dL lower hemoglobin concentration) among patients treated with an ACE inhibitor or ARB. Based upon these findings, it is likely that most patients with PTE will achieve the target hemoglobin level with an ACE inhibitor or ARB alone, without the need for serial phlebotomy. In addition, ACE inhibitors and ARBs are associated with fewer adverse effects compared with
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         . (See
         <a class="local">
          'Theophylline'
         </a>
         below.)
        </p>
        <p>
         A dose-dependent decrease in hemoglobin and/or hematocrit values is observed in &gt;90 percent of PTE patients within two to six weeks of treatment with an ACE inhibitor or ARB [
         <a href="#rid1">
          1,2,13,15,16,25,69,70,84-86,90
         </a>
         ]. The nadir hematocrit is usually reached within three to six months, and the attained level remains stable with continued treatment during long-term observation [
         <a href="#rid15">
          15,17,86,91,92
         </a>
         ]. If the ACE inhibitor or ARB is discontinued, the hematocrit values rise gradually over the next three months toward pretreatment levels in the majority of patients. However, erythrocytosis does not recur in a substantial fraction of patients (20 to 30 percent) who discontinue treatment [
         <a href="#rid71">
          71,85
         </a>
         ].
        </p>
        <p>
         Direct comparisons between ACE inhibitors and ARBs for the treatment of PTE are limited [
         <a href="#rid33">
          33,84
         </a>
         ]. One randomized trial compared the efficacy of
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         (10 mg/day) and
         <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">
          losartan
         </a>
         (50 mg/day) in 27 patients with PTE [
         <a href="#rid84">
          84
         </a>
         ]. The response rate (as defined by a &gt;1 g/dL decrease in hemoglobin levels) was similar with both drugs (75 to 80 percent), but enalapril produced a greater reduction in hemoglobin concentration in the responders (3.3 versus 1.7 g/dL). Cessation of therapy led to a return to baseline hemoglobin levels in 10 of 13 patients. There was a trend for a slower return to baseline after discontinuation of losartan (seven versus three months for enalapril). A high frequency of relapse has also been noted in other studies [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         ARBs are less commonly associated with side effects including cough and angioedema. Both ACE inhibitors and ARBs may cause kidney dysfunction, postural hypotension, hyperkalemia, and erectile dysfunction. These side effects are dose dependent and generally improve after dose reduction. Severe adverse reactions, such as angioneurotic edema or anaphylactoid reactions, have not been reported in patients with PTE [
         <a href="#rid13">
          13,15,91
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">
          "Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Cough'
         </a>
         .)
        </p>
        <p>
         The mechanisms underlying the ACE inhibitor-induced decrease in erythrocytes are unknown, although one study has suggested that ACE inhibitors induce apoptosis of the erythroid precursors [
         <a href="#rid47">
          47
         </a>
         ]. In addition, renin-angiotensin system (RAS) inhibition may decrease erythropoietin production and restore the observed/expected serum erythropoietin ratio toward normal range [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H584645989">
         <span class="h2">
          Phlebotomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic phlebotomy can be used for patients with PTE who have a contraindication to receiving an ACE inhibitor or ARB (eg, due to intolerance or known allergy) or in whom an ACE inhibitor or ARB is ineffective at reducing the hemoglobin concentration. (See
         <a class="local">
          'Overview of treatment'
         </a>
         above.)
        </p>
        <p>
         A standard one unit phlebotomy (500 mL) should reduce the hematocrit by 3 percentage points in a normal-sized adult (eg, from 46 to 43 percent). Phlebotomy of 500 mL of blood should be performed at intervals appropriate for patient size and tolerability to achieve and maintain a target hemoglobin of &lt;17 g/dL (hematocrit &lt;51 percent).
        </p>
        <p>
         Once a hemoglobin level &lt;17 g/dL has been stably maintained, we attempt to withdraw phlebotomy while continuing treatment with an ACE inhibitor or ARB.
        </p>
        <p>
         Excessive therapeutic phlebotomy may result in the development of iron deficiency. Iron replacement therapy should be administered cautiously with close monitoring of blood counts since it may provoke a rapid rise in the hemoglobin level.
        </p>
        <p>
         Phlebotomy is quite effective in normalizing hematocrits and may be used chronically for PTE. This was demonstrated in a study of 12 kidney transplant recipients with PTE (defined by hemoglobin &gt;17 g/dL or hematocrit &gt;52 percent) who underwent phlebotomy (500 mL), repeated an average of three times within the first two weeks until hematocrit decreased below 45 percent [
         <a href="#rid93">
          93
         </a>
         ]. Phlebotomy reduced hematocrit from 54.8 percent at baseline to 44.3 percent after two weeks and 43.0 percent after six weeks.
        </p>
        <p class="headingAnchor" id="H1918135429">
         <span class="h2">
          Less frequently used therapies
         </span>
        </p>
        <p class="headingAnchor" id="H3087782695">
         <span class="h3">
          Theophylline
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who do not respond to ACE inhibitors or ARBs or have a contraindication to their use and who do not wish to undergo repeated phlebotomy,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         is an effective alternative therapy. However, theophylline has a narrow therapeutic window and, even at relatively small doses, can cause side effects (such as headache, nervousness, and insomnia) and adversely affect the patient's quality of life. (See
         <a class="medical medical_review" href="/z/d/html/6501.html" rel="external">
          "Theophylline poisoning", section on 'Pharmacology and cellular toxicology'
         </a>
         .)
        </p>
        <p>
         In patients with PTE,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         can be administered as an extended-release oral formulation at a dose of 8 mg/kg of body weight per day [
         <a href="#rid94">
          94
         </a>
         ]. The initiation, dose titration, and monitoring of theophylline in patients with PTE are similar to that for patients receiving theophylline for the treatment of asthma. These issues are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/560.html" rel="external">
          "Theophylline use in asthma", section on 'Safe use of theophylline'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          Theophylline
         </a>
         appears to act as an adenosine antagonist in this setting, suggesting that adenosine facilitates both the release of and the bone marrow response to erythropoietin. In a prospective trial of eight patients with PTE and five normal controls, an eight week course of theophylline reduced the hematocrit from 58 to 46 percent in those with PTE and from 43 to 39 percent in the control group [
         <a href="#rid94">
          94
         </a>
         ]. Other studies found that theophylline can lower the hematocrit by 8 to 15 percent [
         <a href="#rid32">
          32,95
         </a>
         ].
        </p>
        <p>
         However,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         is not as predictably effective as an ACE inhibitor [
         <a href="#rid85">
          85
         </a>
         ]. As an example, one report of 28 patients with PTE compared theophylline,
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         , and no treatment [
         <a href="#rid85">
          85
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among the 10 patients who received
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         , the hematocrit decreased from 57 to 45 percent at two months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among the nine patients administered 600 mg/day of
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         (given in two doses), the average hematocrit was reduced from 56 to 52 percent but remained above 51 percent in five.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nine patients did not receive medical treatment for PTE. After three months, PTE persisted in eight.
        </p>
        <p>
        </p>
        <p>
         Another study that compared
         <a class="drug drug_general" data-topicid="8620" href="/z/d/drug information/8620.html" rel="external">
          aminophylline
         </a>
         with
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         showed no response of PTE to aminophylline [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2118482589">
         <span class="h3">
          Antiproliferative agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of antiproliferative agents such as mammalian (mechanistic) target of rapamycin (mTOR) inhibitors (eg,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         ),
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         has been associated with anemia and may decrease the risk of PTE [
         <a href="#rid4">
          4,70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7330.html" rel="external">
          "Anemia and the kidney transplant recipient", section on 'Later (&gt;3 months) posttransplantation'
         </a>
         .)
        </p>
        <p>
         In general, we do not alter the immunosuppression regimen (eg, switch one maintenance immunosuppression medication to
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ) to treat PTE in the absence of other indications (eg, inability to tolerate calcineurin inhibitors). However, altering the immunosuppressive regimen may be considered for patients who do not respond to ACE inhibitors or ARBs or who have a contraindication to their use, do not wish to undergo repeated phlebotomy, and do not wish to start
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         due to perceived side effects, provided it is immunologically permissible.
        </p>
        <p>
         In one study, PTE occurred more frequently among graft recipients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         A compared with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [
         <a href="#rid70">
          70
         </a>
         ]. Another study of 214 kidney-pancreas recipients found a lower incidence of PTE among patients treated with
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         compared with those treated with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (7 versus 19 percent, respectively) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H287557967">
         <span class="h2">
          Patients with a thromboembolic event
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historically, thromboembolic complications were relatively common in untreated patients with PTE; however, studies of patients undergoing treatment with ACE inhibitors or ARBs for PTE have shown very low rates of thrombosis. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
         There are no studies to guide the optimal treatment of patients with PTE who develop an acute thromboembolic event. In general, our approach to the management of thromboembolic complications in patients with PTE is similar to that for patients with polycythemia vera and other forms of secondary erythrocytosis who develop thromboembolic complications, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4534.html" rel="external">
          "Polycythemia vera and secondary polycythemia: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         Patients with PTE who develop a venous thromboembolic event should be treated appropriately with anticoagulation, but there are no studies that have examined the optimal anticoagulant or duration of anticoagulation in a patient with PTE and a first episode of venous thromboembolism. General management of venous thromboembolism is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         .)
        </p>
        <p>
         Patients with PTE who develop an arterial thromboembolic event (eg, stroke, limb ischemia) should be treated as described separately. (See
         <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">
          "Initial assessment and management of acute stroke"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112120.html" rel="external">
          "Embolism to the lower extremities"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H224881514">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">
          "Society guideline links: Kidney transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25596288">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Posttransplant erythrocytosis (PTE) is defined as a hemoglobin concentration &gt;17 g/dL and/or hematocrit &gt;51 percentage points that occurs following transplantation, persists for more than six months, and occurs in the absence of another underlying cause. It is reported to occur in 8 to 15 percent of kidney transplant recipients. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – PTE most often occurs within the first 8 to 24 months after transplantation. Symptoms may include malaise, headache, plethora, lethargy, and dizziness. Historically, thromboembolic complications were relatively common in untreated patients with PTE; however, subsequent studies of patients undergoing treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for PTE have shown very low rates of thrombosis. Relapse is common after treatment is discontinued. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of PTE is made by the demonstration of a hemoglobin &gt;17 g/dL and/or hematocrit &gt;51 percent that persists for over six months after transplantation and by the exclusion of other common causes of nontransplant-associated erythrocytosis, including malignancies and, in selected patients, chronic obstructive pulmonary disease (COPD) or obstructive sleep apnea (OSA). (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – For kidney transplant recipients with PTE, we suggest treating all patients to lower the hemoglobin concentration (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). The primary goals of treatment are to control symptoms and reduce the risk of thromboembolic events. The optimal hemoglobin among patients with PTE is not known. We generally target a hemoglobin level &lt;17 g/dL (hematocrit &lt;51 percent) in both males and females. Our overall approach to therapy, which is largely consistent with the guidelines of the British Society of Haematology, is as follows (see
         <a class="local">
          'Overview of treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For all patients with PTE and a hemoglobin &gt;17, we suggest treatment with either an ACE inhibitor or an ARB rather than phlebotomy or
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We generally use an ARB such as
         <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">
          losartan
         </a>
         at 50 mg/day. The dose may be increased to 100 mg/day if no response is observed within four weeks. Patients who do not respond to an ARB may respond to an ACE inhibitor such as
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         , although patients who do not respond to one ACE inhibitor are generally equally unresponsive to all other ACE inhibitors, as well as ARBs. (See
         <a class="local">
          'ACE inhibitors or ARBs in all patients'
         </a>
         above and
         <a class="local">
          'Evidence for ACE inhibitors/ARBs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who do not respond to ARBs or ACE inhibitors at the maximum tolerated dose, we suggest therapeutic phlebotomy rather than other therapies such as
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         or antiproliferative agents (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Phlebotomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In general, our approach to the management of thromboembolic complications in patients with PTE is similar to that for patients with polycythemia vera and other forms of secondary erythrocytosis who develop thromboembolic complications. (See
         <a class="medical medical_review" href="/z/d/html/4534.html" rel="external">
          "Polycythemia vera and secondary polycythemia: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2431997998">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Daniel C Brennan, MD, FACP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int 2003; 63:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4:2001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiberd BA. Post-transplant erythrocytosis: a disappearing phenomenon? Clin Transplant 2009; 23:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einollahi B, Lessan-Pezeshki M, Nafar M, et al. Erythrocytosis after renal transplantation: review of 101 cases. Transplant Proc 2005; 37:3101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wickre CG, Norman DJ, Bennison A, et al. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int 1983; 23:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler M, Hestin D, Mayeux D, et al. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Clin Nephrol 1996; 45:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatman AJ, Tucker B, Amess JA, et al. Erythraemia in renal transplant recipients treated with cyclosporin. Lancet 1988; 1:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qunibi WY, Barri Y, Devol E, et al. Factors predictive of post-transplant erythrocytosis. Kidney Int 1991; 40:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollak R, Maddux MS, Cohan J, et al. Erythrocythemia following renal transplantation: influence of diuretic therapy. Clin Nephrol 1988; 29:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razeghi E, Kaboli A, Pezeshki ML, et al. Risk factors of erythrocytosis post renal transplantation. Saudi J Kidney Dis Transpl 2008; 19:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skreb N, Hofman L. Effect of dibutyryl cAMP and theophylline on cultured rat embryonic shields. Experientia 1977; 33:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danovitch GM, Jamgotchian NJ, Eggena PH, et al. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation 1995; 60:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrone LF, Di Paolo S, Logoluso F, et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 1997; 64:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torregrosa JV, Campistol JM, Montesinos M, et al. Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up. Transplantation 1994; 58:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conlon PJ, Farrell J, Donohoe J, Walshe JJ. The beneficial effect of enalapril on erythrocytosis after renal transplantation. Transplantation 1993; 56:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lal SM, Trivedi HS, Ross G Jr. Long term effects of ACE inhibitors on the erythrocytosis in renal transplant recipients. Int J Artif Organs 1995; 18:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thevenod F, Radtke HW, Grützmacher P, et al. Deficient feedback regulation of erythropoiesis in kidney transplant patients with polycythemia. Kidney Int 1983; 24:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagher FJ, Ramos E, Erslev A, et al. Erythrocytosis after renal allotransplantation: treatment by removal of the native kidneys. South Med J 1980; 73:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernández E, Morales JM, Andrés A, et al. Usefulness and safety of treatment with captopril in posttransplant erythrocytosis. Transplant Proc 1995; 27:2239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alasfar S, Hall IE, Mansour SG, et al. Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation. BMC Nephrol 2021; 22:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abouelenein RK, Refaie AF, Alhendy YA, et al. Posttransplant Erythrocytosis Among Egyptian Living-Donor Kidney Transplant Recipients. Exp Clin Transplant 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill M, Leung M, Luo CY, et al. Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport-2 inhibitor. Clin Transplant 2023; 37:e15013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagher FJ, Ramos E, Erslev AJ, et al. Are the native kidneys responsible for erythrocytosis in renal allorecipients? Transplantation 1979; 28:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frei D, Guttmann RD, Gorman P. A matched-pair control study of postrenal transplant polycythemia. Am J Kidney Dis 1982; 2:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaston RS, Julian BA, Diethelm AG, Curtis JJ. Effects of enalapril on erythrocytosis after renal transplantation. Ann Intern Med 1991; 115:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schramek A, Better OS, Adler O, et al. Hypertensive crisis, erythrocytosis, and uraemia due to renal-artery stenosis of kidney transplants. Lancet 1975; 1:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacon BR, Rothman SA, Ricanati ES, Rashad FA. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med 1980; 140:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerra G, Indahyung R, Bucci CM, et al. Elevated incidence of posttransplant erythrocytosis after simultaneous pancreas kidney transplantation. Am J Transplant 2010; 10:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aeberhard JM, Schneider PA, Vallotton MB, et al. Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation 1990; 50:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilan Y, Dranitzki-Elhallel M, Rubinger D, et al. Erythrocytosis after renal transplantation. The response to theophylline treatment. Transplantation 1994; 57:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang AY, Yu AW, Lam CW, et al. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis 2002; 39:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiykim AA, Genctoy G, Horoz M, et al. Serum stem cell factor level in renal transplant recipients with posttransplant erythrocytosis. Artif Organs 2009; 33:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brox AG, Mangel J, Hanley JA, et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation 1998; 66:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirshenbaum AS, Goff JP, Kessler SW, et al. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992; 148:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamperi S, Carozzi S. Erythroid progenitor growth in erythrocytosic transplanted patients. Artif Organs 1985; 9:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Díez J. Insulin-like growth factor I in essential hypertension. Kidney Int 1999; 55:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen C, Coulon S, Bhukhai K, et al. Erythrocytosis associated with IgA nephropathy. EBioMedicine 2022; 75:103785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010; 56:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gossmann J, Burkhardt R, Harder S, et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 2001; 60:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100:2310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glicklich D, Kapoian T, Mian H, et al. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation 1999; 68:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azizi M, Ezan E, Nicolet L, et al. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cole J, Ertoy D, Lin H, et al. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 2000; 106:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glicklich D, Burris L, Urban A, et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol 2001; 12:1958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih LY, Huang JY, Lee CT. Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J Am Soc Nephrol 1999; 10:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kedzierska K, Kabat-Koperska J, Safranow K, et al. Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients. Clin Transplant 2008; 22:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000; 275:26765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishizaka N, Saito K, Furuta K, et al. Angiotensin II-induced regulation of the expression and localization of iron metabolism-related genes in the rat kidney. Hypertens Res 2007; 30:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tajima S, Ikeda Y, Enomoto H, et al. Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice. Eur J Nutr 2015; 54:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kujawa-Szewieczek A, Kolonko A, Kocierz M, et al. Association between gene polymorphisms of the components of the renin-angiotensin-aldosteron system, graft function, and the prevalence of hypertension, anemia, and erythrocytosis after kidney transplantation. Transplant Proc 2011; 43:2957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato H, Ishida J, Matsusaka T, et al. Erythropoiesis and Blood Pressure Are Regulated via AT1 Receptor by Distinctive Pathways. PLoS One 2015; 10:e0129484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remynse LC, Begun FP, Jacobs SC, Lawson RK. Juxtaglomerular cell tumor with elevation of serum erythropoietin. J Urol 1989; 142:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erkelens DW, Statius van Eps LW. Bartter's syndrome and erythrocytosis. Am J Med 1973; 55:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991; 17:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross NB, Webster AC, Masson P, et al. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev 2009; :CD003598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann Intern Med 2001; 134:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plata R, Cornejo A, Arratia C, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002; 359:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrlin B, Nyquist O, Sylvén C. Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study. Br Heart J 1991; 66:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005; 45:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odabas AR, Cetinkaya R, Selcuk Y, et al. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva Med 2003; 45:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ertürk S, Nergizoğlu G, Ateş K, et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14:1912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunlay SM, Weston SA, Redfield MM, et al. Anemia and heart failure: a community study. Am J Med 2008; 121:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheungpasitporn W, Thongprayoon C, Chiasakul T, et al. Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis. QJM 2015; 108:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavlidis G, Papageorgiou SG, Bazani E, et al. Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes. Ther Adv Hematol 2021; 12:2040620720958299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis 2001; 38:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rell K, Koziak K, Jarzyo I, et al. Correction of posttransplant erythrocytosis with enalapril. Transplantation 1994; 57:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perazella M, McPhedran P, Kliger A, et al. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Julian BA, Gaston RS, Barker CV, et al. Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Kidney Int 1994; 46:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, et al. Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol 2006; 85:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai SF, Tarng DC. Anemia in patients of diabetic kidney disease. J Chin Med Assoc 2019; 82:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reis M, Tavares J, Malheiro J, et al. Is Erythrocytosis More Common After Simultaneous Pancreas Kidney Transplantation? A Single-Center Experience. Transplant Proc 2023; 55:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marathias KP, Lambadiari VA, Markakis KP, et al. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes. Am J Nephrol 2020; 51:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross M, Goldwasser E. On the mechanism of erythropoietin-induced differentiation. XIV. The apparent effect of etiocholanolone on initiation of erythropoiesis. Exp Hematol 1976; 4:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanjani ED, Banisadre M. Hormonal stimulation of erythropoietin production and erythropoiesis in anephric sheep fetuses. J Clin Invest 1979; 64:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen AH, Johannessen A, Poulsen K. Inactive plasma renin exhibits sex difference in mice. Clin Sci (Lond) 1989; 76:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maktouf C, Yaich S, Aloui S, et al. Angiogenic activity in the sera of patients with post-kidney transplant erythrocytosis. Saudi J Kidney Dis Transpl 2014; 25:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelrahman M, Rafi A, Ghacha R, et al. Post-transplant erythrocytosis: a review of 47 renal transplant recipients. Saudi J Kidney Dis Transpl 2004; 15:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basri N, Gendo MZ, Haider R, et al. Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia. Exp Clin Transplant 2007; 5:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alzoubi B, Kharel A, Osman F, et al. Incidence, risk factors, and outcomes of post-transplant erythrocytosis after kidney transplantation. Clin Transplant 2021; 35:e14166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMullin MFF, Mead AJ, Ali S, et al. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. Br J Haematol 2019; 184:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 2001; 72:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ok E, Akçiçek F, Töz H, et al. Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation. Transplantation 1995; 59:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montanaro D, Groupuzzo M, Boscutti G, et al. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms. Clin Nephrol 2000; 53:suppl 47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klaassen RJ, van Gelder T, Rischen-Vos J, et al. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation 1997; 64:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Midtvedt K, Stokke ES, Hartmann A. Successful long-term treatment of post-transplant erythrocytosis with losartan. Nephrol Dial Transplant 1996; 11:2495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7:2350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gossmann J, Thürmann P, Bachmann T, et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGregor MS, Rowe PA, Watson MA, et al. Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. Nephron 1996; 74:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducloux D, Fournier V, Bresson-Vautrin C, Chalopin JM. Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transpl Int 1998; 11:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barenbrock M, Spieker C, Rahn KH, Zidek W. Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis. Clin Nephrol 1993; 40:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakris GL, Sauter ER, Hussey JL, et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990; 323:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grekas D, Dioudis C, Valkouma D, et al. Theophylline modulates erythrocytosis after renal transplantation. Nephron 1995; 70:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzali M, Filho GA. Use of aminophylline and enalapril in posttransplant polycythemia. Transplantation 1998; 65:1461.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7348 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8023814" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Posttransplant erythrocytosis: an enigma revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12631334" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Posttransplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15575902" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191802" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Post-transplant erythrocytosis: a disappearing phenomenon?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16213319" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Erythrocytosis after renal transplantation: review of 101 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6348369" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Postrenal transplant erythrocytosis: a review of 53 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8846535" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2897540" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Erythraemia in renal transplant recipients treated with cyclosporin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1762317" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Factors predictive of post-transplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3282731" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Erythrocythemia following renal transplantation: influence of diuretic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18580013" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Risk factors of erythrocytosis post renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/201488" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of dibutyryl cAMP and theophylline on cultured rat embryonic shields.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7624954" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9326420" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8053053" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8333046" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The beneficial effect of enalapril on erythrocytosis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7607751" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Long term effects of ACE inhibitors on the erythrocytosis in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6355616" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Deficient feedback regulation of erythropoiesis in kidney transplant patients with polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6992287" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Erythrocytosis after renal allotransplantation: treatment by removal of the native kidneys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7652789" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Usefulness and safety of treatment with captopril in posttransplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33435916" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30501588" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Posttransplant Erythrocytosis Among Egyptian Living-Donor Kidney Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37170711" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport-2 inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/390790" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Are the native kidneys responsible for erythrocytosis in renal allorecipients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9621296" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7048900" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A matched-pair control study of postrenal transplant polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1952492" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of enalapril on erythrocytosis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/46023" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hypertensive crisis, erythrocytosis, and uraemia due to renal-artery stenosis of kidney transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6996630" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Renal artery stenosis with erythrocytosis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20148815" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Elevated incidence of posttransplant erythrocytosis after simultaneous pancreas kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2219284" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8140628" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Erythrocytosis after renal transplantation. The response to theophylline treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11877580" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19958348" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Serum stem cell factor level in renal transplant recipients with posttransplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9808491" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1370517" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3893396" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Erythroid progenitor growth in erythrocytosic transplanted patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9987103" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Insulin-like growth factor I in essential hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34959131" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Erythrocytosis associated with IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20400218" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The role of the renin-angiotensin system in the regulation of erythropoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422739" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9410909" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Angiotensin II stimulates proliferation of normal early erythroid progenitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10428268" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609242" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9369248" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11104792" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518790" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10215331" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18339134" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10837481" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17460390" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Angiotensin II-induced regulation of the expression and localization of iron metabolism-related genes in the rat kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25096756" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21996200" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Association between gene polymorphisms of the components of the renin-angiotensin-aldosteron system, graft function, and the prevalence of hypertension, anemia, and erythrocytosis after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26107632" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Erythropoiesis and Blood Pressure Are Regulated via AT1 Receptor by Distinctive Pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2685372" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Juxtaglomerular cell tumor with elevation of serum erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4356102" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Bartter's syndrome and erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1992663" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Enalapril-associated anemia in renal transplant recipients treated for hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19588343" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Antihypertensive treatment for kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11242510" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11879862" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1931347" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15680718" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12682621" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10462270" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18691487" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Anemia and heart failure: a community study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25697787" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33489062" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11532682" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8165703" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Correction of posttransplant erythrocytosis with enalapril.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7645558" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7853800" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16132904" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31453863" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Anemia in patients of diabetic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37147196" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Is Erythrocytosis More Common After Simultaneous Pancreas Kidney Transplantation? A Single-Center Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32241009" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/954881" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : On the mechanism of erythropoietin-induced differentiation. XIV. The apparent effect of etiocholanolone on initiation of erythropoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/500805" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Hormonal stimulation of erythropoietin production and erythropoiesis in anephric sheep fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2523771" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Inactive plasma renin exhibits sex difference in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25193901" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Angiogenic activity in the sera of patients with post-kidney transplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17642778" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Post-transplant erythrocytosis: a review of 47 renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17617052" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33231331" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Incidence, risk factors, and outcomes of post-transplant erythrocytosis after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30426472" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502994" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7778179" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10809436" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9311722" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9017632" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Successful long-term treatment of post-transplant erythrocytosis with losartan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17845569" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8872973" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8938674" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9704399" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8261683" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2163024" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7617113" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Theophylline modulates erythrocytosis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9645803" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Use of aminophylline and enalapril in posttransplant polycythemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
